Premium
Systemic treatment of psoriasis with an oral retinoic acid derivative (Ro 10‐9359)
Author(s) -
LASSUS ALLAN
Publication year - 1980
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1111/j.1365-2133.1980.tb05692.x
Subject(s) - medicine , desquamation , erythema , dermatology , placebo , psoriasis , etretinate , gastroenterology , pathology , alternative medicine
SUMMARY Ninety‐seven patients with severe psoriasis took part in a 1‐year study to evaluate the effect of a new oral synthetic retinoid (Ro 10‐9359). The trial was performed in a double‐blind cross‐over fashion. The treatment started with either 100 mg daily of Ro 10‐9359 or placebo and the maintenance dose was in most cases 50 mg. Follow‐up examinations were performed monthly and the parameters erythema, desquamation, infiltration and extent of the lesions were followed. Throughout the study there was a significant to highly significant preference for Ro 10‐9359 shown by all parameters. More patients were in complete remission after Ro 10‐9359 periods than after placebo periods. The side‐effects of Ro 10‐9359 on uninvolved skin and mucous membranes seemed to be largely dose‐dependent. Twenty‐three patients interrupted the study, four of them because of side‐effects, mainly alopecia. Laboratory examinations revealed no aberrations which could be attributed to the therapy. One patient developed hepatitis during a placebo period.